McKesson Packaging Services is recalling 24,120 cups of Megestrol Acetate Oral Suspension, USP 400 mg/10mL, which is a prescription medication used to treat loss of appetite and weight loss. This recall was initiated because the drug was found to be subpotent, meaning it did not meet the required strength specifications during stability testing. The affected medication was distributed in boxes containing 20 individual 10 mL unit-dose cups across the United States.
A subpotent drug may not provide the full intended dose of the medication, which can lead to reduced effectiveness of the treatment for the patient's condition.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES ยท Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.